A new, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival, said researchers.
from Medindia Health News https://ift.tt/2tS5N0f
No comments:
Post a Comment